StockData
Nexalin Technology, Inc. logo

Nexalin Technology, Inc. (NXL) stock

NXLNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$1.44−0.06 (-4.00%)

Close on Nov 18, 2026Market cap $31.73MP/E –Yield –

Nexalin Technology r&d expenses

Research and development expenses are spending on new products and technology.

Nexalin Technology's R&D Expenses for the twelve months ending Jun 30, 2026 was $1.36M, down 12.0% year over year. For fiscal 2025 it was $1.08M, down 9.0% from the year before. The highest annual figure on record is $1.92M in fiscal 2023.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.08M-9.0%
FY2024Dec 31, 2024$1.19M-38.0%
FY2023Dec 31, 2023$1.92M+276.1%
FY2022Dec 31, 2022$511.00K+267.6%
FY2021Dec 31, 2021$139.00K-90.7%
FY2020Dec 31, 2020$1.50M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$564.48K+150.0%
Q1 FY2026Mar 31, 2026$346.38K-14.7%
Q4 FY2025Dec 31, 2025$224.94K-69.5%
Q3 FY2025Sep 30, 2025$226.52K+26.9%
Q2 FY2025Jun 30, 2025$225.77K+33.3%
Q1 FY2025Mar 31, 2025$406.29K+284.5%
Q4 FY2024Dec 31, 2024$737.24K+405.0%
Q3 FY2024Sep 30, 2024$178.57K+171.2%
Q2 FY2024Jun 30, 2024$169.41K-52.5%
Q1 FY2024Mar 31, 2024$105.67K-7.0%
Q2 FY2023Jun 30, 2023$146.00K+394.2%
Q1 FY2023Mar 31, 2023$65.83K+469.2%
Q4 FY2022Dec 31, 2022$356.28K+1192.7%
Q3 FY2022Sep 30, 2022$113.62K+239.4%
Q2 FY2022Jun 30, 2022$29.54K–
Q1 FY2022Mar 31, 2022$11.57K–
Q4 FY2021Dec 31, 2021$27.56K–
Q3 FY2021Sep 30, 2021$33.47K–

More Nexalin Technology figures

See a number that looks wrong?